Methyprylon

Summary

Methyprylon (CHEMBL1200790) is an approved small molecule (ATC N05CE02).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CE02
• Chemistry: 183.25 Da · C10H17NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200790
Name	Methyprylon
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4162
ATC	N05CE02
Molecular formula	C10H17NO2
Molecular weight	183.25
InChIKey	SIDLZWOQUZRBRU-UHFFFAOYSA-N

SMILES: CCC1(C(=O)C(CNC1=O)C)CC

IUPAC name: 3,3-diethyl-5-methylpiperidine-2,4-dione

Also known as: Methyprylon, Methyprylone, Metiprilon, Noludar, NSC-30442, METHYPRYLON, METHYPRYLONE, methyprylon

Patent coverage: 839 distinct patent families (3,242 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).